31 results on '"Kumada, Hiromitsu"'
Search Results
2. HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients
3. WED-119 - HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients
4. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
5. A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma
6. Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection
7. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
8. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis – an open-cohort study
9. Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis
10. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
11. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients
12. A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus
13. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
14. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy
15. Effect of interferon therapy on viral titers in patients with chronic hepatitis C who are positive for hepatitis GB virus C
16. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection
17. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
18. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region
19. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
20. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
21. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
22. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
23. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients
24. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
25. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up
26. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels
27. Consistently low hepatitis B virus-DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis
28. Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C
29. Molecular analysis of intraspousal transmission of hepatitis C virus
30. LBO09 - A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma.
31. FRI384 - Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.